UK markets open in 7 hours 33 minutes
NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.34 -0.04 (-0.05%) GOLD FUTURES
2,322.90 -1.30 (-0.06%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
49,849.92 -818.80 (-1.62%)
Evotec SE (EVT.BE)
Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
At close: 09:52PM CEST
| Previous close | 9.61 |
| Open | 9.63 |
| Bid | 9.48 x 145200 |
| Ask | 9.65 x 140700 |
| Day's range | 9.53 - 9.71 |
| 52-week range | 9.17 - 24.36 |
| Volume | |
| Avg. volume | 470 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
- GlobeNewswire
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORMAGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVERALL PROGRAMS HAMBURG, Germany and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) an
© 2024 Yahoo. All rights reserved.